CoChat

TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy

Open access

Published version of a preprint

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 52 of the 70 sources its claims cite were checked for support.

Abstract

Patients with non-small cell lung cancer (NSCLC) with loss of the tumor suppressor gene STK11 are resistant to immune checkpoint therapies like anti-PD-1. In this study, we conducted an in vivo CRISPR screen that identified histone deacetylase 1 as a target to reverse anti-PD-1 resistance driven by loss of STK11 and developed TNG260, a potent small-molecule inhibitor of the CoREST complex with selectivity exceeding previously generated inhibitors in this class in preclinical studies. Treatment with TNG260 led to increased expression of immunomodulatory genes in STK11-deficient cancer cells. When combined with anti-PD-1, TNG260 induced immune-mediated stasis and/or regression in STK11-deficient syngeneic tumor models and autochthonous NSCLC models. In the tumors of patients with STK11-deficient cancers in a clinical trial (NCT05887492), treatment with a combination of TNG260 and pembrolizumab increased intratumoral histone acetylation, PD-L1 tumor proportion scores, and T-cell infiltration into the tumor microenvironment. This study illustrates a promising treatment strategy for addressing immune evasion in patients with STK11-mutant NSCLC. SIGNIFICANCE: Targeting CoREST with TNG260 sensitizes STK11-deficient non-small cell lung cancer to anti-PD-1 immunotherapy, offering a potential treatment for patients not served by existing therapies. See related commentary by Lin and Shen, p. 3821.

Overview

CoChat Summary

## TL;DR

TNG260 is a selective inhibitor of the HDAC1-containing CoREST complex that, in STK11-deficient tumor models, sensitized tumors to anti–PD-1 therapy and remodeled tumor immune activity. In a phase I/II study of TNG260 plus pembrolizumab, on-treatment biopsies showed increased histone acetylation and signs of a more active immune microenvironment.

## Key findings

  • In an in vivo CRISPR screen in MC38 cells, HDAC1 knockout reversed STK11-driven anti–PD-1 resistance; HDAC1 sgRNAs were significantly depleted in both screen comparisons used to identify sensitizing targets.
  • TNG260 was 230 times more potent for HDAC1 and 37 times more potent for HDAC2 than for HDAC3 in biochemical assay, and in cells it had IC50s of 0.10 µmol/L (HDAC1), 0.17 µmol/L (HDAC2), and 1.07 µmol/L (HDAC3).
  • In the MC38_sgStk11 model, TNG260 + anti–PD-1 produced 5 complete regressions in 8 mice, 100% survival to the end of the experiment, and 75% ORR versus 0% with anti–PD-1 alone; after 11 days, 83% TGI was reported for the combination.
  • In the CT26_sgStk11 model, TNG260 + anti–PD-1 produced 88% ORR and 73% TGI after 13 days, with survival improved to 87.5% versus 13 days median survival for anti–PD-1 alone.
  • In the KL GEMM lung model, 75 mg/kg TNG260 + anti–PD-1 caused complete stasis of lung tumor burden for the study duration, while in the KP model the combination did not affect tumor growth.
  • In 10 paired patient biopsies from NCT05887492, 80 and 120 mg TNG260 increased histone H4 lysine 5 acetylation; in paired analyses, 4 of 6 patients had increased intratumoral helper T cells, and 6 of 6 had increased intratumoral cytotoxic T cells, with increased PD-L1 TPS at 80 and 120 mg.

## Methods

  • The study combined in vivo CRISPR screening, cell-based biochemical and binding assays, syngeneic/allograft/GEMM mouse tumor studies, and paired patient biopsy analysis from the phase I/II trial NCT05887492.
  • The screen used MC38 cells with 400 nontargeting sgRNAs and 3,176 sgRNAs targeting 794 genes, followed by anti-IgG2a or anti–PD-1 treatment in mice and next-generation sequencing readout of sgRNA abundance.
  • Analyses included biochemical HDAC assays, NanoBRET target engagement, RNA-seq, ChIP-seq, flow cytometry, NanoString profiling, and standard statistical tests including one-way ANOVA and log-rank tests.

## Limitations

  • The paper states that its in vivo syngeneic models with engineered STK11 loss may differ from STK11-deficient human tumors because the models evolved with intact STK11.
  • It also states that the molecular mechanism underlying the increase in T-cell activity with combination treatment is not yet well understood.
  • Evident from the text: the clinical biopsy analysis is based on 10 biopsies from a phase I/II trial, so the human evidence presented here is small and exploratory.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-25-0998

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. HDAC1 knockout resensitizes STK11-mutant tumors to immune checkpoint blockade. A, Average volumes of MC38_sgNTC tumors in the indicated mouse strain; anti–PD-1 antibody was administered biweekly (N = 8 mice/group). B, Average volume of MC38_sgStk11 tumors in the indicated mouse strain; anti–PD-1 antibody was administered biweekly (N = 8 mice/group). Values are mean ± SEM. One-way ANOVA was used to determine statistical significance. **, P < 0.01; ***, P < 0.001; ns, not significant. C, Scheme describing CRISPR screen using STK11 isogenic MC38 tumors. D, Volcano plot of sgRNAs comparing MC38_sgStk11 tumors in C57BL/6 mice treated with anti–PD-1 with MC38_sgStk11 tumors in athymic nude mice. The green point indicates average sgRNAs for HDAC1. E, Volcano plot of sgRNAs comparing MC38_sgStk11 tumors with MC38_sgNTC tumors in C57BL/6 mice treated with anti–PD-1. The green point indicates average sgRNAs for HDAC1. C, Created in BioRender. Ahronian, L. (2025) https://BioRender.com/mndvf20.
Figure 1. HDAC1 knockout resensitizes STK11-mutant tumors to immune checkpoint blockade. A, Average volumes of MC38_sgNTC tumors in the indicated mouse strain; anti–PD-1 antibody was administered biweekly (N = 8 mice/group). B, Average volume of MC38_sgStk11 tumors in the indicated mouse strain; anti–PD-1 antibody was administered biweekly (N = 8 mice/group). Values are mean ± SEM. One-way ANOVA was used to determine statistical significance. **, P < 0.01; ***, P < 0.001; ns, not significant. C, Scheme describing CRISPR screen using STK11 isogenic MC38 tumors. D, Volcano plot of sgRNAs comparing MC38_sgStk11 tumors in C57BL/6 mice treated with anti–PD-1 with MC38_sgStk11 tumors in athymic nude mice. The green point indicates average sgRNAs for HDAC1. E, Volcano plot of sgRNAs comparing MC38_sgStk11 tumors with MC38_sgNTC tumors in C57BL/6 mice treated with anti–PD-1. The green point indicates average sgRNAs for HDAC1. C, Created in BioRender. Ahronian, L. (2025) https://BioRender.com/mndvf20.CC BY-NC-ND · PubMed Central
Figure 2. TNG260 is a CoREST-selective deacetylase inhibitor. A, Structure of TNG260 aligned with structures of class-I HDAC small-molecule inhibitors; the fluorophenyl substituent is highlighted by the dotted lines. B, Crystal structure of TNG260 bound to HDAC2, with the key hydrogen bond and metal interactions illustrated as dotted lines. C, TNG260’s selectivity for HDAC1/2 over HDAC3 can be understood from the overlay of the reported HDAC3 crystal structure (PDB 4A69, blue) onto the TNG260-bound HDAC2 structure (PDB 9NTB, white). HDAC3’s Leu133 position clashes with the TNG260 fluorophenyl group, whereas HDAC2’s Leu140 position allows tight ligand binding but would clash with HDAC3’s Tyr107. D, Inhibition of the indicated HDAC enzyme in Fluor de Lys deacetylase assay by 3 hours of incubation with a dose response of TNG260. Plots are averages of N = 2 experiments. E, Western blotting of acetyl-H3K9 in the MC38 cell line treated with a dose response of TNG260 for 72 hours. F, Cellular HDAC1, HDAC2, and HDAC3 NanoBRET assay with a dose response of TNG260 incubated for 3 hours. Plots are averages of N = 2 experiments. G, Heat map showing IC50s of purified HDAC complexes profiled in an in vitro deacetylase assay with the indicated compounds.
Figure 2. TNG260 is a CoREST-selective deacetylase inhibitor. A, Structure of TNG260 aligned with structures of class-I HDAC small-molecule inhibitors; the fluorophenyl substituent is highlighted by the dotted lines. B, Crystal structure of TNG260 bound to HDAC2, with the key hydrogen bond and metal interactions illustrated as dotted lines. C, TNG260’s selectivity for HDAC1/2 over HDAC3 can be understood from the overlay of the reported HDAC3 crystal structure (PDB 4A69, blue) onto the TNG260-bound HDAC2 structure (PDB 9NTB, white). HDAC3’s Leu133 position clashes with the TNG260 fluorophenyl group, whereas HDAC2’s Leu140 position allows tight ligand binding but would clash with HDAC3’s Tyr107. D, Inhibition of the indicated HDAC enzyme in Fluor de Lys deacetylase assay by 3 hours of incubation with a dose response of TNG260. Plots are averages of N = 2 experiments. E, Western blotting of acetyl-H3K9 in the MC38 cell line treated with a dose response of TNG260 for 72 hours. F, Cellular HDAC1, HDAC2, and HDAC3 NanoBRET assay with a dose response of TNG260 incubated for 3 hours. Plots are averages of N = 2 experiments. G, Heat map showing IC50s of purified HDAC complexes profiled in an in vitro deacetylase assay with the indicated compounds.CC BY-NC-ND · PubMed Central
Figure 3. TNG260 reverses resistance to anti–PD-1 in STK11-deficient tumor models. A, Mouse plasma levels of unbound (u) TNG260 after 2 days of once daily oral treatment with TNG260 at the indicated dose (N = 4 mice/group). The IC50 of HDAC1 in the cellular NanoBRET assay is indicated by the dotted red line. B, Relative amounts of acetyl-H3K9 normalized to histone 3 from tumor tissue at the doses indicated, quantified from Western blotting. Each time point is normalized to the vehicle control tumors (N = 4 mice/group). C, Relative levels of acetyl-H3K9 normalized to histone H3 following 7 days of TNG260 treatment at the indicated dose, quantified from Western blotting (N = 3 representative tumors/group). Values are average ± SD. A t test was used for statistical analysis comparing each treatment with vehicle control. D, Individual MC38_sgStk11 tumor volumes treated with anti-IgG2a and TNG260 (once daily orally) at 30 mg/kg, anti–PD-1 (intraperitoneally twice weekly) at 10 mg/kg, or the combination of TNG260 and anti–PD-1 (N = 8 mice/group). ORR was calculated from the sum of mice with a partial regression and complete regression. Statistical analysis was performed by one-way ANOVA for the combination arm versus anti–PD-1. E and F, Survival curve of the indicated treatment groups in the MC38_sgStk11 study from D (E) or CT26_sgStk11 from Supplementary Fig. S4 (F). Statistical analysis was performed comparing the combination TNG260 and anti–PD-1 groups versus the anti–PD-1 groups by log-rank tests. G, Inhibition of HDAC1 and HDAC3 as determined by cellular NanoBRET assay plotted by free exposures of TNG260 in vivo. Shaded box indicates efficacious exposures of TNG260 in mouse. H, Average tumor volumes of animals previously cured of MC38_sgStk11 tumors with combination treatment (N = 5) compared with an untreated, naïve cohort (N = 8). Mice were rechallenged with MC38_sgStk11 tumor cells and tumor volume was evaluated over time. I and J, Average tumor volumes of MC38_sgStk11 tumors in C57BL/6 (I) and BALB/c athymic nude mice (J) treated as indicated (N = 8 mice/group). Statistical comparisons were carried out by one-way ANOVA comparing anti-IgG2a to each treatment group. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; ns, not significant.
Figure 3. TNG260 reverses resistance to anti–PD-1 in STK11-deficient tumor models. A, Mouse plasma levels of unbound (u) TNG260 after 2 days of once daily oral treatment with TNG260 at the indicated dose (N = 4 mice/group). The IC50 of HDAC1 in the cellular NanoBRET assay is indicated by the dotted red line. B, Relative amounts of acetyl-H3K9 normalized to histone 3 from tumor tissue at the doses indicated, quantified from Western blotting. Each time point is normalized to the vehicle control tumors (N = 4 mice/group). C, Relative levels of acetyl-H3K9 normalized to histone H3 following 7 days of TNG260 treatment at the indicated dose, quantified from Western blotting (N = 3 representative tumors/group). Values are average ± SD. A t test was used for statistical analysis comparing each treatment with vehicle control. D, Individual MC38_sgStk11 tumor volumes treated with anti-IgG2a and TNG260 (once daily orally) at 30 mg/kg, anti–PD-1 (intraperitoneally twice weekly) at 10 mg/kg, or the combination of TNG260 and anti–PD-1 (N = 8 mice/group). ORR was calculated from the sum of mice with a partial regression and complete regression. Statistical analysis was performed by one-way ANOVA for the combination arm versus anti–PD-1. E and F, Survival curve of the indicated treatment groups in the MC38_sgStk11 study from D (E) or CT26_sgStk11 from Supplementary Fig. S4 (F). Statistical analysis was performed comparing the combination TNG260 and anti–PD-1 groups versus the anti–PD-1 groups by log-rank tests. G, Inhibition of HDAC1 and HDAC3 as determined by cellular NanoBRET assay plotted by free exposures of TNG260 in vivo. Shaded box indicates efficacious exposures of TNG260 in mouse. H, Average tumor volumes of animals previously cured of MC38_sgStk11 tumors with combination treatment (N = 5) compared with an untreated, naïve cohort (N = 8). Mice were rechallenged with MC38_sgStk11 tumor cells and tumor volume was evaluated over time. I and J, Average tumor volumes of MC38_sgStk11 tumors in C57BL/6 (I) and BALB/c athymic nude mice (J) treated as indicated (N = 8 mice/group). Statistical comparisons were carried out by one-way ANOVA comparing anti-IgG2a to each treatment group. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; ns, not significant.CC BY-NC-ND · PubMed Central
Figure 4. TNG260 sensitizes STK11-deficient lung tumors to anti–PD-1 treatment through transcriptional reprogramming. A and B, Average tumor volumes of KL tumors (N = 15–20 mice/group; A) and KP tumors (N = 5 mice/group; B) in B6-Albino mice, treated as indicated. C, Tumor volume changes measured by MRI scans of cre-induced KL GEMM mice, treated as indicated (N = 8–10 mice/group). Statistical comparisons were carried out by one-way ANOVA comparing anti-IgG2a with each treatment group. **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; ns, not significant. D, Bar chart showing fold change of the expression of genes related to antigen presentation and peptide loading in KL and KP cells treated with 1 µmol/L TNG260 for 7 days. E, Heatmap showing acetyl-H3K9 signal in both KL and KP cell lines treated with DMSO (control) or 1 µmol/L TNG260 (N = 2) for 7 days. ChIP signal intensity is shown by red shading. Genomic regions are clustered into seven groups by k-means (k = 7) clustering. F, Genome browser view at the Cxcl3 locus of KL and KP cell lines treated with DMSO or TNG260 (N = 2). G, Enrichment plot showing positive enrichment of differentially accessible acetyl-H3K9 peaks for genes increased by TNG260 treatment. H, GO analysis of genes from KL tumors in clusters 3 and 4 from Supplementary Fig. S7I. Clusters 3 and 4 were defined as genes with increased acetyl-H3K9 and increased expression with TNG260 treatment. I, Heatmap showing acetyl-H3K9 signals in KL and KP tumors treated with the combination of TNG260 and anti–PD-1. ChIP signal intensity is shown by red shading. Genomic regions are clustered into seven groups by k-means (k = 6) clustering (N = 3–5 mice/group).
Figure 4. TNG260 sensitizes STK11-deficient lung tumors to anti–PD-1 treatment through transcriptional reprogramming. A and B, Average tumor volumes of KL tumors (N = 15–20 mice/group; A) and KP tumors (N = 5 mice/group; B) in B6-Albino mice, treated as indicated. C, Tumor volume changes measured by MRI scans of cre-induced KL GEMM mice, treated as indicated (N = 8–10 mice/group). Statistical comparisons were carried out by one-way ANOVA comparing anti-IgG2a with each treatment group. **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001; ns, not significant. D, Bar chart showing fold change of the expression of genes related to antigen presentation and peptide loading in KL and KP cells treated with 1 µmol/L TNG260 for 7 days. E, Heatmap showing acetyl-H3K9 signal in both KL and KP cell lines treated with DMSO (control) or 1 µmol/L TNG260 (N = 2) for 7 days. ChIP signal intensity is shown by red shading. Genomic regions are clustered into seven groups by k-means (k = 7) clustering. F, Genome browser view at the Cxcl3 locus of KL and KP cell lines treated with DMSO or TNG260 (N = 2). G, Enrichment plot showing positive enrichment of differentially accessible acetyl-H3K9 peaks for genes increased by TNG260 treatment. H, GO analysis of genes from KL tumors in clusters 3 and 4 from Supplementary Fig. S7I. Clusters 3 and 4 were defined as genes with increased acetyl-H3K9 and increased expression with TNG260 treatment. I, Heatmap showing acetyl-H3K9 signals in KL and KP tumors treated with the combination of TNG260 and anti–PD-1. ChIP signal intensity is shown by red shading. Genomic regions are clustered into seven groups by k-means (k = 6) clustering (N = 3–5 mice/group).CC BY-NC-ND · PubMed Central
Figure 5. TNG260 modifies the tumor immune microenvironment in patients with STK11-deficient tumors. A, Percentage of acetylated histone H4 Lys5 compared with total acetylated and unacetylated histone H4 detected by mass spectrometry in FFPE tissue collected before and in study. B, TPS of PD-L1 from FFPE tissue biopsies collected in A. C and D, FFPE tissue biopsies analyzed by multiplex immunofluorescence for helper T cells (CD3+/CD4+; C) and cytotoxic T cells (CD3+/CD8+; D), respectively. Quantifications were performed in tumor regions identified by hematoxylin and eosin. E, Exemplar paired biopsy of a patient with NSCLC (patient 9; Supplementary Table S6) imaged by multiplex immunofluorescence for the indicated markers before and during treatment with 120 mg TNG260 and pembrolizumab. Scale bar, 50 µm. *, P ≤ 0.05.
Figure 5. TNG260 modifies the tumor immune microenvironment in patients with STK11-deficient tumors. A, Percentage of acetylated histone H4 Lys5 compared with total acetylated and unacetylated histone H4 detected by mass spectrometry in FFPE tissue collected before and in study. B, TPS of PD-L1 from FFPE tissue biopsies collected in A. C and D, FFPE tissue biopsies analyzed by multiplex immunofluorescence for helper T cells (CD3+/CD4+; C) and cytotoxic T cells (CD3+/CD8+; D), respectively. Quantifications were performed in tumor regions identified by hematoxylin and eosin. E, Exemplar paired biopsy of a patient with NSCLC (patient 9; Supplementary Table S6) imaged by multiplex immunofluorescence for the indicated markers before and during treatment with 120 mg TNG260 and pembrolizumab. Scale bar, 50 µm. *, P ≤ 0.05.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

36 Valid · 0 Not valid · 7 Not checked · 148 Own results and interpretations

122 more claims · 14 with their cited sources checked

Create a free account to see all 191 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 21
  • It may state two separate claims as one. 49

Create a free account to see these claims.

Citations

Cites

Show all 47 references

Cited by

See all 9

Metadata

Authors
Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., Spigel, D. R., Wang, J. S., Skoulidis, F., Stephens, J., Meynardie, M., Powell, J. M., Lopez, A., Ranieri, M., Ploszaj, M. A., Tan, Y. J., Lee, Y. T., Yu, Y., Deng, J., Chen, T., McCarren, P., Tsai, A., Hussain, S. S., Doyon, B., Amemiya, K., Ermolieff, J., Shahagadkar, P., Das, N. M., Flynn, L. R., Shields, J. A., Danielczyk, L., McMillan, B. J., Mignault, A., Meier, S. R., Wu, H.-J., Guerin, D. J., Whittington, D. A., Min, C., Sienczylo, I., Maxwell, J. P., DiBenedetto, H. J., Watanabe, H., Haines, B. B., Huang, A., Crystal, A., Andersen, J. N., Wu, X., & Wong, K.-K.
Affiliations
  • Tango Therapeutics (United States) (US)
  • NYU Langone Health (US)
  • Tisch Cancer Institute (US)
  • HealthONE (US)
  • University of California, Los Angeles (US)
  • Virginia Cancer Specialists (US)
  • Sarah Cannon (US)
  • Florida Cancer Specialists & Research Institute (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • The University of Texas Southwestern Medical Center (US)
  • Jnana Therapeutics (United States) (US)
Corresponding author
Wong, Kwok-Kin
Venue
Cancer Research
Published
2025-08-29
Volume
85
Issue
20
Pages
3966-3982
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W4413818083
Cited by
9
References
45
Citations by year
2026: 8 · 2025: 1
FWCI
3.70
Type
journal article
Language
en
Open access
Locations
  • Cancer Research (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
Funders
  • Tango Therapeutics (MA00000054)
  • NYU Langone Medical Center (MA00000054)
  • National Institutes of Health (R01CA293718)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords
CoREST complex, STK11 mutation, non-small cell lung cancer, anti-PD-1 resistance, immune checkpoint inhibitors, HDAC1, histone acetylation, pembrolizumab, tumor immune evasion, CRISPR screen, tumor microenvironment, T cell infiltration, PD-L1 expression
MeSH terms
Immune Checkpoint Inhibitors, AMP-Activated Protein Kinase Kinases, Animals, Carcinoma, Non-Small-Cell Lung, Female, Humans, Immunotherapy, Lung Neoplasms, Mutation, Protein Serine-Threonine Kinases, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, AMP-Activated Protein Kinases, Tumor Microenvironment, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-25-0998
The paper
Ahronian, L. G., Sahu, S., Zhang, M., Patel, A. S., Geng, K., Bhattacharya, R., Falchook, G. S., Goldman, J. W., Spira, A. I., Punekar, S. R., Spigel, D. R., Wang, J. S., Skoulidis, F., Stephens, J., Meynardie, M., Powell, J. M., Lopez, A., Ranieri, M., Ploszaj, M. A., . . . Wong, K.-K. (2025). TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-25-0998

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.